Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.
Adeera LevinVlado PerkovicDavid C WheelerStefan HantelJyothis T GeorgeMaximilian von EynattenAudrey Koitka-WeberChristoph Wannernull nullPublished in: Clinical journal of the American Society of Nephrology : CJASN (2020)
EMPA-REG OUTCOME, NCT01131676.